This is a demo store. No orders will be fulfilled.

Innovations in Cell, Gene, and Protein Therapies, Regenerative Medicine, Synthetic Biology, Epitranscriptomics, and CRISPR Editing

Innovations in Cell, Gene, and Protein Therapies, Regenerative Medicine, Synthetic Biology, Epitranscriptomics, and CRISPR Editing

RELEASE DATE
15-Mar-2019
REGION
Global
Deliverable Type
Technology Alert
Research Code: D759-00-06-00-00
SKU: HC03277-GL-TA_24246
$950.00
In stock
SKU
HC03277-GL-TA_24246
$950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The Life Science, Health & Wellness TechVision Opportunity Engine (TOE) details technology innovations across cell and gene therapies, regenerative medicine, synthetic biology, epitranscriptomics, CRISPR editing, biological computing, multiplexed assay and liquid biopsy platforms. It also comprises emerging developments across mass spectrometry, vaccines, protein therapies, transplantation techniques, small molecule, and organ-on-a-chip technologies.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Cell therapy, gene therapy, small molecule therapy, protein therapy, epitranscriptomics, biological computing, synthetic biology, vaccines, 3D bioprinting, organ-on-a-chip, gene editing, CRISPR, multiplex assays, qPCR, liquid biopsy, regenerative medicine, transplantation, mass spectrometry, precision medicine

Table of Contents

Advances in Cell, Gene, and Protein Therapies, Regenerative Medicine, Synthetic Biology, Epitranscriptomics, and CRISPR Editing

  • Cartherics
  • Cartherics
  • Immuno-therapy
  • Cell Therapies
  • Cell Therapies
  • Cell Therapies
  • Cynata Therapeutics
  • Cynata Therapeutics
  • Cynata Therapeutics
  • Mesoblast
  • Mesoblast
  • Mesoblast
  • Orthocell
  • Orthocell
  • Orthocell
  • AMSilk
  • AMSilk
  • AMSilk
  • VLPbio
  • VLPbio
  • VLPbio
  • David H. Koch Institute for Integrative Cancer Research at MIT
  • David H. Koch Institute for Integrative Cancer Research at MIT
  • David H. Koch Institute for Integrative Cancer Research at MIT
  • Gotham Therapeutics
  • Gotham Therapeutics
  • Gotham Therapeutics
  • Beam Therapeutics
  • Beam Therapeutics
  • Beam Therapeutics
  • IQVIA
  • IQVIA
  • IQVIA
  • Microsoft
  • Microsoft
  • Microsoft
  • OMass Therapeutics
  • OMass Therapeutics
  • OMass Therapeutics
  • Nightstar Therapeutics
  • Nightstar therapeutics
  • Nightstar Therapeutics
  • University of Minnesota
  • University of Minnesota
  • University of Minnesota
  • SpeeDx Diagnostics
  • SpeeDx Diagnostics
  • SpeeDx Diagnostics
  • Medicago
  • Medicago
  • Medicago
  • Mammoth Biosciences
  • Mammoth Biosciences
  • Mammoth Biosciences
  • Guardant Health
  • Guardant Health
  • Guardant Health
  • Horizon Pharma
  • Horizon Pharma
  • Horizon Pharma
  • Paragonix Technologies
  • Paragonix Technologies
  • Paragonix Technologies
  • Immunomedics
  • Immunomedics
  • Immunomedics
  • Achieve Life Sciences
  • Achieve Life Sciences
  • Achieve Life Sciences
  • Neurocrine Biosciences
  • Neurocrine Biosciences
  • Neurocrine Biosciences
  • InSphero
  • InSphero
  • InSphero
  • Bio-Rad
  • Bio-Rad
  • Bio-Rad
  • Key Contacts
  • Key Contacts (continued)
  • Key Contacts (continued)
  • Key Contacts (continued)
  • Key Contacts (continued)
  • Key Contacts (continued)
The Life Science, Health & Wellness TechVision Opportunity Engine (TOE) details technology innovations across cell and gene therapies, regenerative medicine, synthetic biology, epitranscriptomics, CRISPR editing, biological computing, multiplexed assay and liquid biopsy platforms. It also comprises emerging developments across mass spectrometry, vaccines, protein therapies, transplantation techniques, small molecule, and organ-on-a-chip technologies. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Cell therapy, gene therapy, small molecule therapy, protein therapy, epitranscriptomics, biological computing, synthetic biology, vaccines, 3D bioprinting, organ-on-a-chip, gene editing, CRISPR, multiplex assays, qPCR, liquid biopsy, regenerative medicine, transplantation, mass spectrometry, precision medicine
More Information
Deliverable Types Technology Alert
No Index No
Podcast No
Industries Healthcare
WIP Number D759-00-06-00-00
Is Prebook No
Ti Codes D759